Rob J Vandebriel

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1983874/rob-j-vandebriel-publications-by-year.pdf
Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

113 papers	4,102 citations	34 h-index	61 g-index
125 ext. papers	4,578 ext. citations	4.9 avg, IF	5.23 L-index

#	Paper	IF	Citations
113	Regulation of Neurotoxin Expression by Culture Conditions.. *Toxins*, **2022**, 14,	4.9	1
112	A Decision Support System for preclinical assessment of nanomaterials in medical products: the REFINE DSS.. *Drug Delivery and Translational Research*, **2022**, 1	6.2	0
111	Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances.. *Drug Delivery and Translational Research*, **2022**, 1	6.2	1
110	Pathways Related to NLRP3 Inflammasome Activation Induced by Gold Nanorods. *International Journal of Molecular Sciences*, **2022**, 23, 5763	6.3	0
109	Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines. *Vaccine*, **2021**, 39, 2506-2516	4.1	6
108	Mechanism of Action of TiO: Recommendations to Reduce Uncertainties Related to Carcinogenic Potential. *Annual Review of Pharmacology and Toxicology*, **2021**, 61, 203-223	17.9	14
107	A methodology for developing key events to advance nanomaterial-relevant adverse outcome pathways to inform risk assessment. *Nanotoxicology*, **2021**, 15, 289-310	5.3	14
106	Optimization of an air-liquid interface cell co-culture model to estimate the hazard of aerosol exposures. *Journal of Aerosol Science*, **2021**, 153, 105703	4.3	9
105	Applicability of organ-on-chip systems in toxicology and pharmacology. *Critical Reviews in Toxicology*, **2021**, 51, 540-554	5.7	2
104	Overcoming scientific barriers in the transition from to non-animal batch testing of human and veterinary vaccines. *Expert Review of Vaccines*, **2021**, 20, 1221-1233	5.2	2
103	Airborne particulate matter from goat farm increases acute allergic airway responses in mice. *Inhalation Toxicology*, **2020**, 32, 265-277	2.7	
102	Livestock farm particulate matter enhances airway inflammation in mice with or without allergic airway disease. *World Allergy Organization Journal*, **2020**, 13, 100114	5.2	4
101	A next-generation sequencing based method for determining genetic stability in Clostridium tetani vaccine strains. *Biologicals*, **2020**, 64, 10-14	1.8	1
100	Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, **2020**, 12, e1633	9.2	5
99	The value of organs-on-chip for regulatory safety assessment. *ALTEX: Alternatives To Animal Experimentation*, **2020**, 37, 208-222	4.3	9
98	An Air-liquid Interface Bronchial Epithelial Model for Realistic, Repeated Inhalation Exposure to Airborne Particles for Toxicity Testing. *Journal of Visualized Experiments*, **2020**,	1.6	8
97	Impact of Nanoparticles on Dendritic Cells. *Molecular and Integrative Toxicology*, **2020**, 73-82	0.5	0

96	Sensitive method for endotoxin determination in nanomedicinal product samples. *Nanomedicine*, **2019**, 14, 1231-1246	5.6	8
95	Role of chemical composition and redox modification of poorly soluble nanomaterials on their ability to enhance allergic airway sensitisation in mice. *Particle and Fibre Toxicology*, **2019**, 16, 39	8.4	4
94	A practical approach to assess inhalation toxicity of metal oxide nanoparticles in vitro. *Journal of Applied Toxicology*, **2018**, 38, 160-171	4.1	15
93	The crystal structure of titanium dioxide nanoparticles influences immune activity in vitro and in vivo. *Particle and Fibre Toxicology*, **2018**, 15, 9	8.4	28
92	Pattern of risks of rheumatoid arthritis among patients using statins: A cohort study with the clinical practice research datalink. *PLoS ONE*, **2018**, 13, e0193297	3.7	9
91	Multi-omics approaches confirm metal ions mediate the main toxicological pathways of metal-bearing nanoparticles in lung epithelial A549 cells. *Environmental Science: Nano*, **2018**, 5, 1506-1517	7.1	18
90	Immunotoxicology: A brief history, current status and strategies for future immunotoxicity assessment. *Current Opinion in Toxicology*, **2017**, 5, 55-59	4.4	18
89	Considerations for Safe Innovation: The Case of Graphene. *ACS Nano*, **2017**, 11, 9574-9593	16.7	68
88	The effect of zirconium doping of cerium dioxide nanoparticles on pulmonary and cardiovascular toxicity and biodistribution in mice after inhalation. *Nanotoxicology*, **2017**, 11, 794-808	5.3	11
87	Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study. *Annals of the Rheumatic Diseases*, **2017**, 76, 1723-1730	2.4	9
86	Drivers and barriers in the consistency approach for vaccine batch release testing: Report of an international workshop. *Biologicals*, **2017**, 48, 1-5	1.8	8
85	Nanomedicinal products: a survey on specific toxicity and side effects. *International Journal of Nanomedicine*, **2017**, 12, 6107-6129	7.3	33
84	Immunotoxicity Testing of Nanomedicinal Products: Possible Pitfalls in Endotoxin Determination. *Current Bionanotechnology*, **2017**, 2, 95-102		7
83	State of the art in non-animal approaches for skin sensitization testing: from individual test methods towards testing strategies. *Archives of Toxicology*, **2016**, 90, 2861-2883	5.8	76
82	Towards a nanospecific approach for risk assessment. *Regulatory Toxicology and Pharmacology*, **2016**, 80, 46-59	3.4	88
81	A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements. *International Journal of Nanomedicine*, **2016**, 11, 2935-52	7.3	39
80	Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. *ALTEX: Alternatives To Animal Experimentation*, **2016**, 33, 272-321	4.3	161
79	Risk assessment of titanium dioxide nanoparticles via oral exposure, including toxicokinetic considerations. *Nanotoxicology*, **2016**, 10, 1515-1525	5.3	95

78	Horizon scan of nanomedicinal products. *Nanomedicine*, **2015**, 10, 1599-608	5.6	52
77	In vitro innate immune cell based models to assess whole cell Bordetella pertussis vaccine quality: a proof of principle. *Biologicals*, **2015**, 43, 100-9	1.8	9
76	Sub-chronic toxicity study in rats orally exposed to nanostructured silica. *Particle and Fibre Toxicology*, **2014**, 11, 8	8.4	137
75	Comparison of the molecular topologies of stress-activated transcription factors HSF1, AP-1, NRF2, and NF-B in their induction kinetics of HMOX1. *BioSystems*, **2014**, 124, 75-85	1.9	13
74	Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats. *Particle and Fibre Toxicology*, **2014**, 11, 21	8.4	58
73	Toward a mechanism-based in vitro safety test for pertussis toxin. *Human Vaccines and Immunotherapeutics*, **2014**, 10, 1391-5	4.4	4
72	Response to Statins accelerate the onset of collagen type II-induced arthritis in mice authors reply. *Arthritis Research and Therapy*, **2013**, 15, 403	5.7	
71	Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated dose toxicity study in rats. *Biomaterials*, **2013**, 34, 8333-43	15.6	202
70	Identification of biomarkers to detect residual pertussis toxin using microarray analysis of dendritic cells. *Vaccine*, **2013**, 31, 5223-31	4.1	6
69	Statin use and markers of immunity in the Doetinchem cohort study. *PLoS ONE*, **2013**, 8, e77587	3.7	6
68	Strategies for the optimisation of in vivo experiments in accordance with the 3Rs philosophy. *Regulatory Toxicology and Pharmacology*, **2012**, 63, 140-54	3.4	24
67	Allergic contact dermatitis: epidemiology, molecular mechanisms, in vitro methods and regulatory aspects. Current knowledge assembled at an international workshop at BfR, Germany. *Cellular and Molecular Life Sciences*, **2012**, 69, 763-81	10.3	231
66	Distribution, elimination, and toxicity of silver nanoparticles and silver ions in rats after 28-day oral exposure. *ACS Nano*, **2012**, 6, 7427-42	16.7	515
65	Statins accelerate the onset of collagen type II-induced arthritis in mice. *Arthritis Research and Therapy*, **2012**, 14, R90	5.7	18
64	Statin-associated polymyalgia rheumatica. An analysis using WHO global individual case safety database: a case/non-case approach. *PLoS ONE*, **2012**, 7, e41289	3.7	22
63	Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users. *Pharmacoepidemiology and Drug Safety*, **2012**, 21, 835-43	2.6	7
62	A review of mammalian toxicity of ZnO nanoparticles. *Nanotechnology, Science and Applications*, **2012**, 5, 61-71	3.9	319
61	Dendritic cell-based in vitro assays for vaccine immunogenicity. *Human Vaccines and Immunotherapeutics*, **2012**, 8, 1323-5	4.4	14

60	Use of statins is associated with an increased risk of rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **2012**, 71, 648-54	2.4	44
59	The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. *ALTEX: Alternatives To Animal Experimentation*, **2012**, 29, 411-25	4.3	66
58	Response of MUTZ-3 dendritic cells to the different components of the Haemophilus influenzae type B conjugate vaccine: towards an in vitro assay for vaccine immunogenicity. *Vaccine*, **2011**, 29, 5114-21	4.1	12
57	Respiratory sensitization: advances in assessing the risk of respiratory inflammation and irritation. *Toxicology in Vitro*, **2011**, 25, 1251-8	3.6	13
56	Association between statin use and lupus-like syndrome using spontaneous reports. *Seminars in Arthritis and Rheumatism*, **2011**, 41, 373-81	5.3	24
55	Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. *Toxicological Sciences*, **2010**, 117, 81-9	4.4	62
54	Non-animal sensitization testing: state-of-the-art. *Critical Reviews in Toxicology*, **2010**, 40, 389-404	5.7	63
53	In vitro testing for direct immunotoxicity: state of the art. *Methods in Molecular Biology*, **2010**, 598, 401-23	1.4	46
52	Profiling Adverse Immune Effects. *Methods and Principles in Medicinal Chemistry*, **2009**, 439-469	0.4	
51	The role of Toll-like receptor-4 in pertussis vaccine-induced immunity. *BMC Immunology*, **2008**, 9, 21	3.7	31
50	Supplementation of whole-cell pertussis vaccines with lipopolysaccharide analogs: modification of vaccine-induced immune responses. *Vaccine*, **2008**, 26, 899-906	4.1	11
49	In vitro approaches to the assessment of immunotoxicity. *Toxicology Letters*, **2007**, 172, S6-S7	4.4	
48	Genetic variation in the response to vaccination. *Public Health Genomics*, **2007**, 10, 201-17	1.9	52
47	Consequences of the expression of lipopolysaccharide-modifying enzymes for the efficacy and reactogenicity of whole-cell pertussis vaccines. *Microbes and Infection*, **2007**, 9, 1096-103	9.3	12
46	Comparative gene expression profiling in two congenic mouse strains following Bordetella pertussis infection. *BMC Microbiology*, **2007**, 7, 88	4.5	5
45	Lung response to Bordetella pertussis infection in mice identified by gene-expression profiling. *Immunogenetics*, **2007**, 59, 555-64	3.2	16
44	Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice. *Vaccine Journal*, **2007**, 14, 821-9		32
43	Toll-like receptor 4 polymorphism associated with the response to whole-cell pertussis vaccination in children from the KOALA study. *Vaccine Journal*, **2007**, 14, 1377-80		18

42	Effects of a diphtheria-tetanus-acellular pertussis vaccine on immune responses in murine local lymph node and lung allergy models. *Vaccine Journal*, **2007**, 14, 211-9		1
41	Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis. *Vaccine*, **2007**, 25, 2346-60	4.1	11
40	Toxicogenomics in the assessment of immunotoxicity. *Methods*, **2007**, 41, 132-41	4.6	28
39	In vitro immunotoxicity of bis(tri-n-butyltin)oxide (TBTO) studied by toxicogenomics. *Toxicology*, **2007**, 237, 35-48	4.4	45
38	Cytokine Measurement Tools for Immunotoxicology. *Methods in Pharmacology and Toxicology*, **2007** , 17-30	1.1	1
37	Host genetics of Bordetella pertussis infection in mice: significance of Toll-like receptor 4 in genetic susceptibility and pathobiology. *Infection and Immunity*, **2006**, 74, 2596-605	3.7	36
36	Development of the "Cell Chip": a new in vitro alternative technique for immunotoxicity testing. *Toxicology*, **2005**, 206, 245-56	4.4	16
35	An European inter-laboratory validation of alternative endpoints of the murine local lymph node assay: first round. *Toxicology*, **2005**, 212, 60-8	4.4	49
34	In vitro assessment of sensitizing activity of low molecular weight compounds. *Toxicology and Applied Pharmacology*, **2005**, 207, 142-8	4.6	40
33	Detection of immunotoxicity using T-cell based cytokine reporter cell lines ("Cell Chip"). *Toxicology*, **2005**, 206, 257-72	4.4	18
32	An European inter-laboratory validation of alternative endpoints of the murine local lymph node assay: 2nd round. *Toxicology*, **2005**, 212, 69-79	4.4	40
31	Assessment of potency of allergenic activity of low molecular weight compounds based on IL-1alpha and IL-18 production by a murine and human keratinocyte cell line. *Toxicology*, **2005**, 210, 95-109	4.4	56
30	The Use of In Vitro Systems for Evaluating Immunotoxicity: The Report and Recommendations of an ECVAM Workshop. *Journal of Immunotoxicology*, **2005**, 2, 61-83	3.1	44
29	Toxicogenomics of subchronic hexachlorobenzene exposure in Brown Norway rats. *Environmental Health Perspectives*, **2004**, 112, 782-91	8.4	55
28	Gene polymorphisms within the immune system that may underlie drug allergy. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2004**, 369, 125-32	3.4	7
27	Effect of prolonged exposure to low antigen concentration for sensitization. *Toxicology*, **2003**, 184, 23-30	4.4	11
26	Impact of exposure duration by low molecular weight compounds on interferon-gamma and interleukin-4 mRNA expression and production in the draining lymph nodes of mice. *Toxicology*, **2003**, 188, 1-13	4.4	27
25	Association of Bordetella pertussis with host immune cells in the mouse lung. *Microbial Pathogenesis*, **2003**, 35, 19-29	3.8	29

24	Determination of the sensitising activity of the rubber contact sensitisers TMTD, ZDMC, MBT and DEA in a modified local lymph node assay and the effect of sodium dodecyl sulfate pretreatment on local lymph node responses. *Toxicology*, **2002**, 176, 123-34	4.4	31
23	Cytokine Production Induced by Low-Molecular-Weight Chemicals as a Function of the Stimulation Index in a Modified Local Lymph Node Assay: An Approach to Discriminate Contact Sensitizers from Respiratory Sensitizers. *Toxicology and Applied Pharmacology*, **2002**, 184, 46-56	4.6	66
22	Ranking of allergenic potency of rubber chemicals in a modified local lymph node assay. *Toxicological Sciences*, **2002**, 66, 226-32	4.4	37
21	Cytokine Production Induced by Low-Molecular-Weight Chemicals as a Function of the Stimulation Index in a Modified Local Lymph Node Assay: An Approach to Discriminate Contact Sensitizers from Respiratory Sensitizers **2002**, 184, 46-46		3
20	Cytokine production induced by low-molecular-weight chemicals as a function of the stimulation index in a modified local lymph node assay: an approach to discriminate contact sensitizers from respiratory sensitizers. *Toxicology and Applied Pharmacology*, **2002**, 184, 46-56	4.6	3
19	Comparison of dose-responses of contact allergens using the guinea pig maximization test and the local lymph node assay. *Toxicology*, **2001**, 167, 207-15	4.4	30
18	Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors. *Environmental Health Perspectives*, **2001**, 109, 757-64	8.4	94
17	Interleukin-10 is an unequivocal Th2 parameter in the rat, whereas interleukin-4 is not. *Scandinavian Journal of Immunology*, **2000**, 52, 519-24	3.4	13
16	A quantitative method for assessing the sensitizing potency of low molecular weight chemicals using a local lymph node assay: employment of a regression method that includes determination of the uncertainty margins. *Toxicology*, **2000**, 146, 49-59	4.4	71
15	Assessment of preferential T-helper 1 or T-helper 2 induction by low molecular weight compounds using the local lymph node assay in conjunction with RT-PCR and ELISA for interferon-gamma and interleukin-4. *Toxicology and Applied Pharmacology*, **2000**, 162, 77-85	4.6	76
14	In vitro exposure effects of cyclosporin A and bis(tri-n-butyltin)oxide on lymphocyte proliferation, cytokine (receptor) mRNA expression, and cell surface marker expression in rat thymocytes and splenocytes. *Toxicology*, **1999**, 135, 49-66	4.4	26
13	Environmental and lifestyle factors may act in concert to increase the prevalence of respiratory allergy including asthma. *Clinical and Experimental Allergy*, **1999**, 29, 1303-8	4.1	16
12	UVB exposure-induced systemic modulation of Th1- and Th2-mediated immune responses. *Immunology*, **1999**, 97, 506-14	7.8	101
11	Effects of in vivo exposure to bis(tri-n-butyltin)oxide, hexachlorobenzene, and benzo(a)pyrene on cytokine (receptor) mRNA levels in cultured rat splenocytes and on IL-2 receptor protein levels. *Toxicology and Applied Pharmacology*, **1998**, 148, 126-36	4.6	34
10	Altered cytokine (receptor) mRNA expression as a tool in immunotoxicology. *Toxicology*, **1998**, 130, 43-67	4.4	21
9	Risk assessment and immunotoxicology. *Toxicology Letters*, **1998**, 102-103, 261-5	4.4	14
8	A helper T-cell epitope of the E7 protein of human papillomavirus type 16 in BALB/c mice. *Virus Research*, **1995**, 37, 13-22	6.4	3
7	[9] Methods in immunotoxicology. *Methods in Neurosciences*, **1995**, 151-169		4

6	Specific T-cell factors that initiate cellular immune responses are produced by CD4-, CD8-, V beta 8-lymphocytes and are present in nude mice. *Cellular Immunology*, **1994**, 159, 1-14	4.4	
5	Specific T-cell factor production and lymphocytes in the direct surroundings of a subcutaneous allogeneic tumor. *Cellular Immunology*, **1992**, 144, 269-86	4.4	
4	Initial immunochemical characterization of specific macrophage-arming factor. *Cancer Immunology, Immunotherapy*, **1989**, 30, 21-7	7.4	4
3	Production of specific macrophage-arming factor precedes cytotoxic T lymphocyte activity in vivo during tumor rejection. *Cancer Immunology, Immunotherapy*, **1989**, 30, 28-33	7.4	17
2	Differences in the induction of macrophage cytotoxicity by the specific T lymphocyte factor, specific macrophage arming factor (SMAF), and the lymphokine, macrophage activating factor (MAF). *Immunobiology*, **1989**, 179, 131-44	3.4	8
1	Toxicogenomics as a Tool to Assess Immunotoxicity127-142		